Alnylam Pharmaceuticals has experienced a significant surge in its stocks, following the successful results of their heart disease drug. The company has reportedly submitted a regulatory application to the European Medicines Agency for the treatment of ATTR Amyloidosis with Cardiomyopathy. Some of its drugs including Amvuttra & Givlaari have been the solid fuel behind Alnylam's rising revenues amid fierce competition. Alnylam has also been defending itself against a patent lawsuit filed by Moderna, regarding COVID shots. Their recent financial results for Q3 2024 show positive growth and the company has projected it will break even in the near future. However, insider activities reveal top executives at Alnylam selling off shares worth US$5.0m, which suggests a level of hesitancy. Biotech veteran and Alnylam founding CEO John Maraganore is back in the limelight, launching a new RNAi start-up, intiating a debate over next-generation RNAi potential.
Alnylam Pharmaceuticals News Analytics from Thu, 15 Feb 2024 08:00:00 GMT to Sat, 19 Oct 2024 18:01:46 GMT -
Rating 8
- Innovation 6
- Information 6
- Rumor -6
